- Home
- CRDF vs CNTX Comparison
CRDF vs CNTX Comparison
Compare CRDF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDF | CNTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.1M | 116.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRDF | CNTX |
|---|---|---|
| Price | $2.93 | $1.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $10.63 | $5.67 |
| AVG Volume (30 Days) | ★ 914.5K | 719.9K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $501,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.90 | $0.49 |
| 52 Week High | $5.00 | $1.55 |
Technical Indicators
Market Signals| Indicator | CRDF | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 76.82 | 56.78 |
| Support Level | $2.32 | $1.07 |
| Resistance Level | $2.59 | $1.10 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 99.34 | 58.82 |
Price Performance
Historical ComparisonAbout CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.